Three franchises, one week, and a clear pattern when you line up the issue dates. The first days of June 2026 saw a cluster of biotech grants that, read together, function as a map of where the sector is putting its IP energy: gene editing, cystic fibrosis, and retinal disease.
Gene editing led the week. On June 2, the Broad Institute's US12644111B2 ("CRISPR enzymes and systems") and US12644136B2 (CRISPR delivery to hematopoietic stem cells) issued, alongside Vertex's US12644137B2 on treating hemoglobinopathies. That's the platform (Broad) and the application (Vertex) issuing in the same window — a snapshot of how a foundational tool and a commercial product sit in one ecosystem.
Cystic fibrosis supplied the week's competitive signal. Sionna Therapeutics' US12649750B2 ("Macrocyclic compounds," June 9) is a rival entering the CFTR-modulator space long dominated by one company. A single grant doesn't move a franchise, but it's the kind of filing worth flagging: new chemistry aimed at an established target.
Eye disease rounded out the cluster, and it was the most crowded. Regeneron's US12649031B2 (pre-filled syringes to reduce intraocular inflammation) and Novartis's US12649781B2 (brolucizumab for diabetic retinopathy) both issued June 9, with Kodiak's US12643958B2 (eye disorders) on June 2. Three anti-VEGF-era grants in two weeks is a fair definition of a contested field.
What ties the week together is not a single theme but a distribution. The grants spread across metabolic-adjacent gene therapy, small-molecule CF drugs, and biologic eye treatments — the three pillars this desk tracks. When issued patents cluster like this across exactly the sector's marquee franchises, it's a reminder that the commercial fight is fought continuously in the patent office, not just at the FDA.
The roundup's discipline, as always, every patent named here is a real issued grant with a verifiable date and assignee, deep-linked so you can check it. No orphan claims. A quiet week for trials can still be a loud one for grants — and this was a loud one.